AngioDynamics, Inc. (ANGO) Receives Average Rating of “Buy” from Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $23.00.

A number of equities analysts have issued reports on the stock. Canaccord Genuity boosted their price objective on shares of AngioDynamics from $20.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, January 7th. BidaskClub cut shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 6th. Finally, Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective on the stock in a research report on Wednesday, January 23rd.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its position in shares of AngioDynamics by 41.6% during the third quarter. AQR Capital Management LLC now owns 101,943 shares of the medical instruments supplier’s stock valued at $2,216,000 after buying an additional 29,953 shares during the period. Nordea Investment Management AB increased its position in shares of AngioDynamics by 27.8% during the third quarter. Nordea Investment Management AB now owns 208,523 shares of the medical instruments supplier’s stock valued at $4,533,000 after buying an additional 45,410 shares during the period. Wells Fargo & Company MN increased its position in shares of AngioDynamics by 2.0% during the third quarter. Wells Fargo & Company MN now owns 1,103,646 shares of the medical instruments supplier’s stock valued at $23,993,000 after buying an additional 21,218 shares during the period. LS Investment Advisors LLC increased its position in shares of AngioDynamics by 419.1% during the fourth quarter. LS Investment Advisors LLC now owns 6,909 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 5,578 shares during the period. Finally, Vanguard Group Inc increased its position in shares of AngioDynamics by 2.0% during the third quarter. Vanguard Group Inc now owns 2,144,291 shares of the medical instruments supplier’s stock valued at $46,617,000 after buying an additional 42,134 shares during the period. Institutional investors own 99.90% of the company’s stock.

Shares of ANGO stock traded up $0.06 during mid-day trading on Friday, reaching $21.75. The stock had a trading volume of 554,300 shares, compared to its average volume of 179,861. AngioDynamics has a 52-week low of $15.26 and a 52-week high of $24.49. The stock has a market capitalization of $807.73 million, a price-to-earnings ratio of 29.39 and a beta of 0.75. The company has a current ratio of 2.88, a quick ratio of 1.86 and a debt-to-equity ratio of 0.25.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Friday, January 4th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.01. AngioDynamics had a net margin of 5.10% and a return on equity of 5.85%. The firm had revenue of $91.50 million for the quarter, compared to analysts’ expectations of $89.24 million. During the same quarter in the previous year, the company earned $0.16 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. Equities analysts predict that AngioDynamics will post 0.86 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: What is dollar cost averaging (DCA)?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.